Heartland Veterinary Suppply & Pharmacy
Contact Us

Dormosedan Injectable


PFIZER Dormosedan Injectable - 5ml


PFIZER Dormosedan Injectable - 5ml

  • Veterinarian Prescription (Rx) Required
  • Free Shipping
  • Sedative and Analgesic for use in horses only
  • detomidine hydrochloride
  • Sterile solution - 10 mg/mL
Options:
5 mL - Injectable Free Shipping
20 mL - Injectable Free Shipping
SKU: 3200-RX
Price: $99.95

Quantity:
by Pfizer

RX required for this item.
Click here for our full Prescription Policy and Form


Predictable Sedation
  • a2 selectivity makes DORMOSEDAN predictable and effective
  • Only  a2 -agonist which has significant analgesia extending more than 15 minutes post administration1, 2, 3
  • DORMOSEDAN provides non-narcotic sedation with a wide margin of safety
  • RX Required


INDICATIONS:
Dormosedan® Injectable is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration.

Greater a2 selectivity and dosing flexibility
  • DORMOSEDAN Injectable allows dosing flexibility so you can accurately regulate the depth and length of sedation and analgesia
  • Simple dosing: 1 or 2 mL per 1,100 lbs horse IM or IV
  • Whether administered IV or IM, DORMOSEDAN produces rapid onset of effect (5 minutes for IV,10 to15 minutes for IM)
  • Xylazine can bind with a1 and non-a2 receptor sites, producing variable neurological effects4
  • DORMOSEDAN’s potency is 80 to 100 times greater than xylazine in sedation and analgesic effect5
  • Effects may be maintained up to 2 hours depending on dose level and route of administration, with analgesia being more pronounced following IV injection
  • Additional dosing prolongs not deepens sedation
  • Pfizer Animal Health does not recommend the use at higher than the approved label dosed

DOSAGE AND ADMINISTRATION:

For Sedation: Administer Dormosedan Injectable IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan ® per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.

For Analgesia: Administer Dormosedan ® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan ® per 100 kg or 220 lb), depending on the depth and duration of analgesia required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia.

For Both Sedation and Analgesia: Administer Dormosedan ® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan ® per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required.

Before and after injection, the animal should be allowed to rest quietly.

Product Rating: (4.00)   # of Ratings: 1   (Only registered customers can rate)

There are no comments for this product.
DORMOSEDAN®

Zoetis

(detomidine hydrochloride)

Sedative and Analgesic For Use in Horses Only

Sterile Solution

10 mg/mL

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Dormosedan® is a synthetic alpha-2 adrenoreceptor agonist with sedative and analgesic properties. The chemical name is 1H imidazole, 4-[(2,3-dimethylphenyl) methyl]-hydrochloride and the generic name is detomidine hydrochloride. It is a white, crystalline, water-soluble substance having a molecular weight of 222.7. The molecular formula is C12H14N2•HCl.

CHEMICAL STRUCTURE:

Each mL of Dormosedan® contains 10.0 mg detomidine hydrochloride, 1.0 mg methyl paraben, 5.9 mg sodium chloride, and water for injection, q.s.

CLINICAL PHARMACOLOGY: Dormosedan®, a non-narcotic sedative and analgesic, is a potent α2-adrenoreceptor agonist which produces sedation and superficial and visceral analgesia which is dose dependent in its depth and duration. Profound lethargy and a characteristic lowering of the head with reduced sensitivity to environmental stimuli (sounds, etc.) are seen with detomidine. A short period of incoordination is characteristically followed by immobility and a firm stance with front legs well spread. The analgesic effect is most readily seen as an increase in the pain threshold at the body surface. Sensitivity to touch is little affected and in some cases may actually be enhanced.

With detomidine administration, heart rate is markedly decreased, blood pressure is initially elevated, and then a steady decline to normal is seen. A transient change in the conductivity of the cardiac muscle may occur, as evidenced by partial atrioventricular (AV) and sinoauricular (SA) blocks. This change in the conductivity of the cardiac muscle may be prevented by IV administration of atropine at 0.02 mg/kg of body weight.

No effect on blood clotting time or other hematological parameters was encountered at dosages of 20 or 40 mcg/kg of body weight. Respiratory responses include an initial slowing of respiration within a few seconds to 1-2 minutes after administration, increasing to normal within 5 minutes. An initial decrease in tidal volume is followed by an increase.

INDICATIONS: Dormosedan® is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration.

CONTRAINDICATIONS: Dormosedan® should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.

Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals.

WARNINGS: Not for use in horses intended for food. Not for human use. Keep out of reach of children.

HUMAN SAFETY INFORMATION: Care should be taken to assure that detomidine hydrochloride is not inadvertently ingested as safety studies have indicated that the drug is well absorbed when administered orally. Standard ocular irritation tests in rabbits using the proposed market formulation have shown detomidine hydrochloride to be nonirritating to eyes. Primary dermal irritation tests in guinea pigs using up to 5 times the proposed market concentration of detomidine hydrochloride on intact and abraded skin have demonstrated that the drug is nonirritating to skin and is apparently poorly absorbed dermally. However, in accordance with prudent clinical procedures, exposure of eyes or skin should be avoided and affected areas should be washed immediately if exposure does occur. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using loaded syringes to prevent accidental self-injection.

PRECAUTIONS: Before administration, careful consideration should be given to administering Dormosedan® to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10-15 minutes after injection may improve the response to Dormosedan®.

Dormosedan® is a potent α2-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects.

When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain.

Food and water should be withheld until the sedative effect of Dormosedan® has worn off.

ADVERSE REACTIONS: Occasional reports of anaphylactic-like reactions have been received, including 1 or more of the following: urticaria, skin plaques, dyspnea, edema of the upper airways, trembling, recumbency, and death. The use of epinephrine should be avoided since epinephrine may potentiate the effects of α2-agonists. Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. As with all α2-agonists, the potential for isolated cases of hypersensitivity exist, including paradoxical response (excitation).

SIDE EFFECTS: Horses treated with Dormosedan® exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45-60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing.

Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.

OVERDOSAGE: Detomidine hydrochloride is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses.

DOSAGE AND ADMINISTRATION:

For Sedation: Administer Dormosedan® IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.

For Analgesia: Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of analgesia required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia.

For Both Sedation and Analgesia: Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required.

Before and after injection, the animal should be allowed to rest quietly.

STORAGE: Store at controlled room temperature 15°-30°C (59°-86°F) in the absence of light.

HOW SUPPLIED: Dormosedan® is supplied in 5- and 20-mL multidose vials.

NADA #140-862, Approved by FDA

Manufactured by: ORION PHARMA, Orion Corporation, Espoo, Finland

Distributed by: Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc, NY, NY 10017

107224US-8

Made in Finland

75-6290-09

January 2004

Jaakkoo-Taara Oy

NAC No.: 3690095.3

IMPORTANT VETERINARIAN INFORMATION
We are unable to ship prescriptions into Arkansas, Louisiana, Mississippi, and North Carolina
*Required Information. Please complete form for each pet:













*Would you like us to contact your veterinarian for this prescription?








Low Price Guarantee

Low Price Guarantee

If the item has this emblem, we will gladly match any competitors’ current advertised price.

Competitor must be based in the United States, sorry we cannot honor foreign country prices.

Free Shipping

Fast & Free Shipping

Orders received before 1:00pm M-F (CST) will be processed that same business day.

Free shipping on non-vaccine orders of $75 or more (before tax).

Satisfaction Guarantee

Satisfaction Guarantee

Every purchase you make at HeartlandVetSupply.com is covered by our satisfaction guarantee.

If you are not completely satisfied, please contact us within 30 days.

Heartland Veterinary Supply & Pharmacy is a Vet-VIPPS Accredited Pharmacy Veterinary-Verified Internet Practice Site

Because buying prescription drugs from the Internet is easy, finding a safe source for those medicines is not.

Vet VIPPS Accredited

Located in Hastings, Nebraska, Heartland Veterinary Supply & Pharmacy started as a Veterinary Clinic in 1981, specializing in the health and wellness of the equine, canine and feline species. We have a licensed Veterinarian and Pharmacist on site, as well as a helpful team with the knowledge and products you need to keep your horse, dog or cat healthy and happy. The Heartland Staff is dedicated to fast, courteous service. See what our customers are saying.

Compendium of Veterinary Products

Use the online Compendium of Veterinary Products to view prescription products Indications, Dosage, Precautions, Ingredients, and Side Effects

Rx Form Download
Shipping Policy
Return Policy
Request Catalog
Follow Us on Pinterest
Instagram
Newsletter

Arkansas

Louisiana

Mississippi

North Carolina

Connecticut

Delaware

New Hampshire

New Jersey

New York

Illinois


employees
office

Please Note: Images displayed for products may not be identical to the product that you receive, or reflect actual size or dosage.

PHONE: 800-934-9398 | FAX: 888-424-0484

EMAIL us at: info@heartlandvetsupply.com | 401 W. 33rd Street, Hastings, NE 68901

© HeartlandVetSupply.com 2014. All Rights Reserved

Powered by AspDotNetStorefront